Richmond Becomes the UK's First CRO to be Based in 2 Acute NHS Teaching Hospitals

Posted:
3
May 2005

We are delighted to announce that we have opened a new facility at Mayday University Hospital to complement our units and offices in St George’s Hospital and St George’s University of London. This ground breaking move means Richmond Pharmacology is the UK’s first CROwith a dedicated Phase I and clinical trials unit to be based in 2 acute NHS Teaching Hospitals.Richmond’s pioneering new set-up enables clients to take advantage of on-site therapeutic consultancy with the optional control benefit of in-patient facilities.Dr Jörg Täubel, Managing Director, commented: “We have developed this platform to embrace the new Phase I patient studies. By basing our units and offices in acute university surroundings, we have developed our Integrated Trials Centre to operate as an SMO for Patient Studies. At the core of our offering is the ‘one centre’ solution – consultants, in-patient facilities and patient panels are all managed and delivered from within the same premises. This enables our clients to benefit from a focused, swift and efficient method of delivering Early Phase studies.”Dr Ulrike Lorch, Medical Director, added: “We are delighted and very excited by the opportunities this move offers our clients. Our new 60 bed unit in Mayday Hospital complements our facilities at St George’s Hospital perfectly. Our Phase I studies are conducted within the safety of acute flagship NHS surroundings, and it’s very pleasing to have consultants in numerous specialities just a door away.”“Our units also provide the in-patient control elements which gives our clients the flexibility to conduct Phase I patient studies, with all the benefits of acute NHS Trust facilities. Of course, our clients can still opt for the more traditionally defined Phase I and II studies; but we now offer far greater choice.” concluded Dr Täubel.

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more